AI Global Capital is founded and led by Dr. Stephen G. Odaibo, MD. His unique, multi-disciplinary background provides unparalleled insight into identifying, vetting, and scaling transformative health AI technologies:

​

• Clinical Grounding & Vision:

  • Dr. Odaibo earned his medical degree from Duke University, a leading U.S. medical school. As a practicing Retina Specialist, Dr. Odaibo maintains an acute, first-hand understanding of the challenges of patient care, the urgent need for Value-Based Care models, and the clinical demands that drive the necessity for AI in developing new drugs.

​​

• Deep Technical Authority & Entrepreneurship:

  • Dr. Odaibo is the founder of Deep EigenMatics (Feb 2025), an AI for Drug Discovery company that has established one of the strongest IP portfolios in the space in just 6 months. Dr. Odaibo is the most prolific inventor in the field, with five U.S. Patents granted (assigned to Deep EigenMatics) and 15 U.S. patents filed in 2025 alone for AI drug discovery. He is also the author of the definitive text, "The Foundational Mathematics of Artificial Intelligence," and holds an M.S. in Mathematics from UAB (obtained at age 21) and an M.S. in Computer Science from Duke University.

​​

• Pioneering Drug Discovery Science:

  • Dr. Odaibo conducted two years of wet lab research in the Nobel Prize-winning Lefkowitz Laboratory studying G protein-coupled receptors (GPCRs), which account for over 50% of all druggable targets. This experience grounds the fund's investment in AI for Drug Discovery with foundational molecular science expertise.

​​

• Regulatory & Execution Leadership:

  • Dr. Odaibo designed and led the largest clinical trial for an autonomous AI system ever conducted in the United States. This real-world experience confirms the fund's ability to drive AI technologies through rigorous regulatory and commercialization pathways.

​

• Security & Compliance Rigor:

  • Dr. Odaibo is a Google Cloud Certified Professional Cybersecurity Engineer and former Chair of the highly influential Medical Device Cybersecurity Summit (2024). This expertise ensures that data security, integrity, and regulatory compliance are non-negotiable considerations in all investment due diligence.

​​

• Proven Healthcare Entrepreneurship:

  • Dr. Odaibo is the founder of leading U.S. AI Value-Based Care startup, RETINA-AI HEALTH, Inc., dedicated to diagnosing chronic disease.

​

• Industry Leadership:

  • Dr. Odaibo has been the Chair of the prestigious Medical Device Software Development Summit for Artificial Intelligence since 2022.

​​​​​

​Dr. Stephen G. Odaibo's unique blend of clinical experience, cybersecurity rigor, cutting-edge AI expertise, and proven business acumen provides AI Global Capital with unparalleled insight into identifying and scaling transformative health technologies.

​

A Global Partnership and Perspective

The challenges of healthcare are global, and so is our capital base. Founding Partner Dr. Stephen G. Odaibo's international understanding, built on a foundation of time spent growing up in the U.S., Nigeria, and summers in Taif, Saudi Arabia, positions the fund to identify and scale solutions for diverse international markets.

 

AI Global Capital is currently raising capital via the U.S. Department of Commerce Certified AI Trade Mission, securing Limited Partner commitments from key global financial centers. This global backing is a testament to the universal need for our thesis and positions our portfolio companies for successful international expansion and impact.

​

___________________________________